Contrast study of Entecavir monotherapy and the de novo combining Lamivudine with Adefovir therapy on HBeAg-positive CHB patients with high viral load

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONRC-12002315

Enrollment

Unknown

Registered

2012-06-29

Start date

2011-09-02

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis B

Interventions

group A:combination therapy of LAM with ADV

group B:therapy withETV

Eligibility

Sex/Gender

All

Age

18 Years to 69 Years

Inclusion criteria

Inclusion criteria: NUC-na?ve CHB patients with age between 18 to 60 years and HBeAg positive and HBVDNA over 107copies/ml

Exclusion criteria

Exclusion criteria: Any patients with HCC, decompensated cirrhosis, coinfection with HCV or HIV, concomitant with active heart or renal diseases

Design outcomes

Primary

Measure	Time frame
virological response;	—

Secondary

Measure	Time frame
biochemical response;serological response;virological breakthrough and resistance;safety;	—

Countries

China

Contacts

Public ContactJie Peng

13802515784@163.com+86 13802515784

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026